What types of cancer is Sotolaxib suitable for?

Sotorasib is a targeted drug targeting the KRAS G12C mutation and is mainly used to treat specific types of non-small cell lung cancer (NSCLC). The drug is specifically designed to inhibit the growth of cancer cells with the KRAS G12C mutation, providing patients with a new treatment option.

Indications

1.Non-small cell lung cancer (NSCLC): Sotoraxib is mainly suitable for patients with non-small cell lung cancer who have confirmed KRAS G12C mutations. Non-small cell lung cancer is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. KRAS G12C mutations have a higher incidence in NSCLC. Therefore, the development of sotorasiib provides a new targeted treatment option for these patients.

2.Patients who have failed previous treatment: Sotorasib is mainly used in patients whose disease has progressed despite having received at least one systemic treatment. This includes patients who have received chemotherapy, immunotherapy or other targeted therapies but failed to achieve an effective response. The positioning of this indication aims to bring new hope to patients for whom traditional treatments are ineffective.

Research shows that sotoraxib showed good efficacy in clinical trials. According to clinical trial data, the drug has significant objective response rates and sustained response times in patients with KRAS G12C mutations who have received other treatments. Many patients have experienced tumor shrinkage or stabilization of their condition and improved quality of life after taking sotorasib.

Although the current main indication for sotoraxib is KRAS G12Cmutated non-small cell lung cancer, future studies may expand its scope of application. Scientists are exploring whether other cancer types associated with KRAS mutations, such as pancreatic cancer and colorectal cancer, could also benefit from treatment with sotorasib. In addition, as research progresses, it may be discovered that tumors with other genetic mutations or characteristics are also suitable for treatment with sotoraxib.

Sotoracib is a targeted drug targeting the KRAS G12C mutation. It is mainly suitable for patients with non-small cell lung cancer, especially those who do not respond to other treatments. As more clinical studies are conducted, its indications may be expanded in the future, bringing hope to more patients. Through targeted therapy, sotorasibu provides a new option for patients with non-small cell lung cancer and promotes the advancement of lung cancer treatment.